2026 ACI - CSSO

Friday, April 24, 2026 | 11 a.m.–12:30 p.m. ET
Toronto, Canada

Register Now

This Advances in Cancer Immunotherapy (ACI) program will be held in person at the University of Toronto in conjunction with the Canadian Society of Surgical Oncology (CSSO)’s 2026 Annual Scientific Meeting.

The 2026 SITC Advances in Cancer Immunotherapy Series is supported, in part, through medical education grants from
AstraZeneca Pharmaceuticals, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation. 

Program Faculty

Stephanie Downs-Canner, MD

Stephanie Downs-Canner, MD
Memorial Sloan Kettering Cancer Center 

Mark Faries, MD

Mark Faries, MD
The Angeles Clinic and Research Institute/ Cedars-Sinai

Simon Turcotte, MD, MSC, FRCSC

Simon Turcotte, MD, MSC, FRCSC 
Université de Montréal

Immediate Past President SITC Surgery Committee 

Program Agenda

11–11:05 a.m.

 

Welcome

11:05–11:25 a.m.

 
Update on Neoadjuvant Immunotherapies
Stephanie Downs-Canner, MD – Memorial Sloan Kettering Cancer Center 

11:25–11:30 a.m.

  
Q&A with Dr. Downs-Canner

11:30–11:50 a.m. 

 
Update on Adjuvant Cancer mRNA Vaccines 
Mark Faries, MD – The Angeles Clinic and Research Institute/ Cedars-Sinai

11:50–11:55 a.m. 

 
Q & A with Dr. Faries

11:55 a.m.–12:15 p.m.

 

Update on TIL Therapy for Metastatic Melanoma and Other Cancers
Simon Turcotte, MD, MSC, FRCSC– Université de Montréal

12:15–12:20 p.m.

 
Q&A with Dr. Turcotte

12:20–12:30 p.m.

 

Case Study Panel

12:30 p.m.

 

Closing Remarks

SITC ACI Series

This program is part of the SITC ACI series. View below to explore more programs in the 2026 ACI series.

Program Details

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, interventional radiologists, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Program Learning Objectives

  • Identify cancer immunotherapy approaches used in perioperative settings.

  • Summarize recent updates in cancer immunotherapy in the perioperative setting, and in TIL therapy, including emerging toxicities and management.

  • Implement cancer immunotherapy in the surgical setting appropriately.

Accreditation Information

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of General Surgeons.

 Please visit the CSSO Annual Meeting homepage for full accreditation information.

Disclosure of Conflicts of Interest

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

This 2026 Advances in Cancer Immunotherapy™ program is brought to you in collaboration with the Canadian Society of Surgical Oncology, Advanced Practitioner Society for Hematology and Oncology and the Association of Cancer Care Centers.

Partners for Advancing Clinical Education Logo

The 2026 ACI series is jointly provided by Partners for Advancing Clinical Education (Partners) and the Society for Immunotherapy of Cancer.